Hematologic malignancies research is growing at a rapid pace, increasing the complexity of the field. Advances in the understanding of the mechanisms of hematologic malignancies have resulted in the development of new prognostic models, novel therapies, and improvements in disease management. It is essential to our community to stay abreast of the latest findings in the field and of their potential impaact on clinical practices.
This symposium will provide attendees with cutting-edge updates and perspectives on new diagnostic tools and management options of hematologic malignancies including genetic profiling, cytogenetics, molecular diagnostics, riskadaptive strategies, and novel therapies recently approved by the FDA. Advances in the understanding of aggressive/ indolent lymphoma, myelodysplasia, plasma cell dyscrasia, acute/chronic leukemia and myeloproliferative disease, will be addressed. Advances in newer therapeutic approaches in classical hematology will be reviewed in the Consultative Hematology section.
Registration Deadline: Monday, April 10, 2023